Strain Name:

B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J

Stock Number:

008169

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
The PS19 mouse model harbors the T34 isoform of microtubule-associated protein tau with one N-terminal insert and four microtubule binding repeats (1N4R) encoding the human P301S mutation, all driven by the mouse prion protein promoter. These mice are useful in studying neurofibrillary tangles, neurodegenerative tauopathy and Alzheimer's disease.

Description

Strain Information

Type Mutant Stock; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Mating SystemNoncarrier x Hemizygote         (Female x Male)   11-JUL-08
Specieslaboratory mouse
Generation?+N2F1 (12-DEC-13)
Generation Definitions
 
Donating Investigator Virginia M. Lee,   University of Pennsylvania

Description
These PS19 transgenic mice (P301S Tg mice) express the P301S mutant form of human microtubule-associated protein tau (MAPT), under the direction of the mouse prion protein, Prnp, promoter. The expression of the mutant human MAPT is five-fold higher than the expression of the endogenous mouse MAPT protein. Hyperphosphorylated, insoluble mutant human MAPT protein in the brain accumulates with age causing decreased microtubule binding. At three months of age, transgenic mice exhibit clasping and limb retraction when lifted by the tail, which progresses to limb weakness. By 10 months of age the mice exhibit a hunched back and paralysis, followed by inability to feed. Transgenic mice have a median lifespan of approximately nine months with approximately 80% dying by 12 months. Histological analysis reveals neuron degeneration in hippocampus and ventricular dilatation (brain atrophy) by eight months of age, although significant neuron degeneration in the hippocampus occurs at approximately nine months of age. Neuron loss spreads to the amygdala, neocortex and entorhinal cortex by 12 months of age. Defective translocation of endoplasmic reticulum proteins in affected neurons is observed as early as three months of age. The onset of neurofibrillay tangle formation in the neocortex, amygdala, hippocampus, brain stem and spinal cord is five months of age. Transgenic mice display neuroinflammation with microglial activation and astrogliosis. The ultrastructure of the neurofibrillay tangle-like lesions detected is similar to that found in brain lesions of human Alzheimer's disease and tauopathy patients. Degradation of synaptic function is significant by six months of age. These mice cannot be bred to homozygosity as homozygous females do not mate.

Development
The P301S transgene was designed with the P301S mutant human microtubule-associated protein tau (MAPT*P301S) under the direction of the mouse prion protein promoter (Prnp). This transgene was injected into fertilized B6C3F1 mouse eggs. Transgenic founder animals were bred to B6C3F1/J or B6C3F1/Crl mice to establish founder line 19 (PS19). The resulting PS19 colony was maintained as hemizygotes on the B6C3F1 background before sending to The Jackson Laboratory Repository in 2008.

Control Information

  Control
   Noncarrier
   100010 B6C3F1/J
 
  Considerations for Choosing Controls

Related Strains

Alzheimer's Disease Models
005987   129-Achetm1Loc/J
006409   129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax
008077   129S1/Sv-Bchetm1Loc/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
014556   129S6/SvEv-Apoetm4Mae/J
006555   A.129(B6)-Tg(APPSw)40Btla/Mmjax
005708   B6.129-Apbb1tm1Quhu/J
004714   B6.129-Bace1tm1Pcw/J
004098   B6.129-Klc1tm1Gsn/J
004193   B6.129-Psen1tm1Mpm/J
003615   B6.129-Psen1tm1Shn/J
005300   B6.129-Tg(APPSw)40Btla/Mmjax
005617   B6.129P-Psen2tm1Bdes/J
002609   B6.129P2-Nos2tm1Lau/J
007685   B6.129P2-Psen1tm1Vln/J
007999   B6.129P2-Sorl1Gt(Ex255)Byg/J
008087   B6.129S1-Bchetm1Loc/J
002509   B6.129S2-Plautm1Mlg/J
005301   B6.129S2-Tg(APP)8.9Btla/J
004163   B6.129S4-Cdk5r1tm1Lht/J
010959   B6.129S4-Grk5tm1Rjl/J
010960   B6.129S4-Grk5tm2Rjl/J
002213   B6.129S4-Ngfrtm1Jae/J
006406   B6.129S4-Tg(APPSwLon)96Btla/Mmjax
006469   B6.129S4-Tg(PSEN1H163R)G9Btla/J
012564   B6.129S5-Dhcr24tm1Lex/SbpaJ
004142   B6.129S7-Aplp2tm1Dbo/J
004133   B6.129S7-Apptm1Dbo/J
007251   B6.129X1-Mapttm1Hnd/J
013040   B6.Cg-Apoetm1Unc Ins2Akita/J
005642   B6.Cg-Clutm1Jakh/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
009126   B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
008730   B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
005864   B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
007575   B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J
016197   B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J
005855   B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
004996   B6.Cg-Tg(DBH-Gal)1923Stei/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
004662   B6.Cg-Tg(PDGFB-APP)5Lms/J
006293   B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
005999   B6.Cg-Tg(SBE/TK-luc)7Twc/J
012597   B6.Cg-Tg(Thy1-COL25A1)861Yfu/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
006394   B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
008476   B6;129-Ncstntm1Sud/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
007605   B6;129P-Psen1tm1Vln/J
005618   B6;129P2-Bace2tm1Bdes/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003822   B6;129S-Psen1tm1Shn/J
012639   B6;129S4-Mapttm3(HDAC2)Jae/J
012869   B6;129S6-Apbb2tm1Her/J
006410   B6;129S6-Chattm2(cre)Lowl/J
005993   B6;129S6-Pcsk9tm1Jdh/J
008636   B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
000231   B6;C3Fe a/a-Csf1op/J
008850   B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ
003378   B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J
004462   B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
016556   B6N.129-Ptpn5tm1Pjlo/J
018957   B6N.129S6(B6)-Chattm2(cre)Lowl/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
006554   B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
002328   C.129S2-Plautm1Mlg/J
003375   C3B6-Tg(APP695)3Dbo/Mmjax
005087   C57BL/6-Tg(Camk2a-IDE)1Selk/J
005086   C57BL/6-Tg(Camk2a-MME)3Selk/J
008833   C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J
007027   C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
010800   C57BL/6-Tg(Thy1-PTGS2)300Kand/J
010703   C57BL/6-Tg(Thy1-PTGS2)303Kand/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
007072   CByJ.129P2(B6)-Nos2tm1Lau/J
006472   D2.129(B6)-Tg(APPSw)40Btla/Mmjax
007067   D2.129P2(B6)-Apoetm1Unc/J
013719   D2.Cg-Apoetm1Unc Ins2Akita/J
003718   FVB-Tg(GadGFP)45704Swn/J
013732   FVB-Tg(NPEPPS)1Skar/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
002329   FVB.129S2-Plautm1Mlg/J
003753   FVB/N-Tg(Eno2CDK5R1)1Jdm/J
006143   FVB/N-Tg(Thy1-cre)1Vln/J
008051   NOD.129P2(B6)-Ctsbtm1Jde/RclJ
008390   STOCK Apptm1Sud/J
012640   STOCK Hdac2tm1.2Rdp/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
004779   STOCK Mapttm1(EGFP)Klt/J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
View Alzheimer's Disease Models     (109 strains)

Parkinson's Disease Models
005987   129-Achetm1Loc/J
007587   129S-Park2tm1Rpa/J
002779   129S-Parp1tm1Zqw/J
017001   129S.B6N-Plk2tm1Elan/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
004608   B6(Cg)-Htra2mnd2/J
021828   B6(SJL)-Lrrk2tm3.1Mjff/J
008133   B6.129-Sncbtm1Sud/J
008084   B6.129P2-Drd4tm1Dkg/J
004744   B6.129P2-Esr1tm1Ksk/J
013586   B6.129P2-Gt(ROSA)26Sortm1Nik/J
002609   B6.129P2-Nos2tm1Lau/J
008843   B6.129P2-Sncgtm1Vlb/J
016566   B6.129S-Hcn1tm2Kndl/J
004322   B6.129S1-Mapk10tm1Flv/J
003190   B6.129S2-Drd2tm1Low/J
006582   B6.129S4-Park2tm1Shn/J
017946   B6.129S4-Pink1tm1Shn/J
005934   B6.129S4-Ucp2tm1Lowl/J
004936   B6.129S6(Cg)-Spp1tm1Blh/J
012453   B6.129X1(FVB)-Lrrk2tm1.1Cai/J
017009   B6.129X1-Nfe2l2tm1Ywk/J
009346   B6.Cg-Lrrk2tm1.1Shn/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
006577   B6.Cg-Park7tm1Shn/J
000567   B6.Cg-T2J +/+ Qkqk-v/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
003139   B6.Cg-Tg(DBHn-lacZ)8Rpk/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
012466   B6.Cg-Tg(Lrrk2)6Yue/J
012467   B6.Cg-Tg(Lrrk2*G2019S)2Yue/J
008323   B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J
008321   B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J
008324   B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J
008322   B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J
007894   B6.Cg-Tg(Rgs4-EGFP)4Lvt/J
012588   B6.Cg-Tg(TH-ALPP)1Erav/J
012265   B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J
008859   B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J
008135   B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J
008601   B6.Cg-Tg(Th-cre)1Tmd/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
000544   B6.D2-Cacna1atg/J
012445   B6.FVB-Tg(LRRK2)WT1Mjfa/J
012446   B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J
006660   B6.SJL-Slc6a3tm1.1(cre)Bkmn/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
009688   B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J
008883   B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ
008889   B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ
008886   B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ
009347   B6;129-Lrrk2tm1.1Shn/J
016209   B6;129-Lrrk2tm2.1Shn/J
016210   B6;129-Lrrk2tm3.1Shn/J
013050   B6;129-Pink1tm1Aub/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
006390   B6;129-Sncatm1Sud Sncbtm1.1Sud/J
008532   B6;129-Thtm1(cre/Esr1)Nat/J
008333   B6;129P2-Dldtm1Ptl/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003243   B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J
003692   B6;129X1-Sncatm1Rosl/J
016575   B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J
016576   B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J
004479   B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J
000231   B6;C3Fe a/a-Csf1op/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
013725   B6;SJL-Tg(LRRK2)66Mjff/J
008473   B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J
008134   B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
000506   B6C3Fe a/a-Qkqk-v/J
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
018768   B6N.Cg-Tg(SNCA*E46K)3Elan/J
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
016120   C57BL/6-Lrrk1tm1.1Mjff/J
012444   C57BL/6-Lrrk2tm1Mjfa/J
008389   C57BL/6-Tg(THY1-SNCA)1Sud/J
012769   C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
018785   C57BL/6J-Tg(LRRK2*G2019S)2AMjff/J
018786   C57BL/6J-Tg(LRRK2*R1441G)3IMjff/J
008245   C57BL/6J-Tg(Th-SNCA)5Eric/J
008239   C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J
016122   C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J
016121   C57BL/6N-Lrrk2tm1.1Mjff/J
016123   C57BL/6N-Sncatm1Mjff/J
016936   C57BL/6N-Tg(Thy1-SNCA)12Mjff/J
017682   C57BL/6N-Tg(Thy1-SNCA)15Mjff/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
009610   FVB/N-Tg(LRRK2)1Cjli/J
009609   FVB/N-Tg(LRRK2*G2019S)1Cjli/J
009604   FVB/N-Tg(LRRK2*R1441G)135Cjli/J
009090   FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J
017678   FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J
017744   FVB;129-Tg(Prnp-SNCA*A53T)AAub/J
010710   FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J
010788   FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J
010799   FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
000942   STOCK Pitx3ak/2J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
006340   STOCK Tg(Gad1-EGFP)98Agmo/J
017000   STOCK Tg(SNCA*E46K)3Elan/J
008474   STOCK Tg(THY1-SNCA*A53T)F53Sud/J
008132   STOCK Tg(THY1-Snca)M1mSud/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Parkinson's Disease Models     (112 strains)

Strains carrying   Tg(Prnp-MAPT*P301S)PS19Vle allele
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
View Strains carrying   Tg(Prnp-MAPT*P301S)PS19Vle     (1 strain)

View Strains carrying other alleles of MAPT     (17 strains)

Strains carrying other alleles of Prnp
012938   129-Prnptm2Edin/J
016925   129;B6-Grin3b/Tmem259tm1Zhang Tg(Prnp-C19ORF6,-GFP)6Zhang/J
003960   129S6-Tg(Prnp-GFP/cre)1Blw/J
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
006823   B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J
010700   B6.Cg-Tg(Prnp-TARDBP*A315T)95Balo/J
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
004479   B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J
018917   B6;SJL-Tg(Prnp-CCS)17Jlel/J
003378   B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J
008216   B6CBA(FVB)-Tg(Prnp-TBP*)71-16Xjl/J
008075   B6CBA-Tg(Prnp-TBP*)105Xjl/J
008083   B6CBA-Tg(Prnp-TBP*)13Xjl/J
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
017907   B6N.Cg-Tg(Prnp-TARDBP)96Dwc/J
017933   B6N.Cg-Tg(Prnp-TARDBP*Q331K)103Dwc/J
017930   B6N.Cg-Tg(Prnp-TARDBP*Q331K)109Dwc/J
016201   B6SJL-Tg(Prnp-TARDBP)4Jlel/J
016203   B6SJL-Tg(Prnp-TARDBP*A315T)23Jlel/J
016608   C57BL/6-Tg(Prnp-TARDBP)3cPtrc/J
017604   C57BL/6-Tg(Prnp-TARDBP*M337V)4Ptrc/J
019517   FVB-Tg(Prnp-HSPB1)1Kolb/J
019482   FVB-Tg(Prnp-HSPB1*R136W)1Kolb/J
018122   FVB.129S7(B6)-Prnptm1Cwe/J
017678   FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J
017744   FVB;129-Tg(Prnp-SNCA*A53T)AAub/J
017916   STOCK Tg(Prnp-FUS)WT3Cshw/J
016144   STOCK Tg(Prnp-TARDBP)4Jlel/J
016143   STOCK Tg(Prnp-TARDBP*A315T)23Jlel/J
008212   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(Prnp-SMN)92Ahmb/J
View Strains carrying other alleles of Prnp     (36 strains)

Additional Web Information

Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.

Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Alzheimer Disease; AD
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
Frontotemporal Dementia; FTD   (MAPT)
Parkinson Disease, Late-Onset; PD   (MAPT)
Parkinson-Dementia Syndrome   (MAPT)
Pick Disease of Brain   (MAPT)
Supranuclear Palsy, Progressive, 1; PSNP1   (MAPT)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Tg(Prnp-MAPT*P301S)PS19Vle/0

        involves: C3H * C57BL/6
  • mortality/aging
  • premature death   (MGI Ref ID J:165441)
    • ~80% of mice die by 12 months of age, with median survival of ~9 months   (MGI Ref ID J:119741)
  • behavior/neurological phenotype
  • abnormal spatial learning
    • 6 month old females are able to learn to locate the platform of the Morris water maze during training and latencies to find the visible platform are similar between mutants and wild-type mice, however mutants spend more time in finding the invisible platform, indicating impaired spatial learning ability   (MGI Ref ID J:174441)
    • during the probe trail of the Morris water maze, mutant females show less time and path length in the pool quadrant where the platform had previously been placed and a smaller number of target platform crossings   (MGI Ref ID J:174441)
  • hunched posture   (MGI Ref ID J:165441)
    • paralysis is associated with hunched-back posture   (MGI Ref ID J:119741)
  • limb grasping
    • at 3 months of age, mice exhibit limb grasping and limb retraction when lifted by the tail, whereas mice expressing a wild-type MAPT transgene show no neurodegenerative phenotype up to 24 months of age   (MGI Ref ID J:119741)
  • paralysis
    • mice show paralysis at 7-10 months of age   (MGI Ref ID J:119741)
    • 44% of mutants exhibit paresis or paralysis and presence of a hunchback posture at 11 months of age   (MGI Ref ID J:165441)
  • paresis
    • 44% of mutants exhibit paresis or paralysis and presence of a hunchback posture at 11 months of age   (MGI Ref ID J:165441)
  • weakness
    • limb grasping at 3 months of age is followed by limb weakness   (MGI Ref ID J:119741)
  • nervous system phenotype
  • abnormal CNS synaptic transmission
    • basal synaptic transmission is impaired at 6 months   (MGI Ref ID J:119741)
    • mice show small fiber volley amplitude, fEPSP slopes and amplitudes at all stimulus intensities tested   (MGI Ref ID J:119741)
    • abnormal excitatory postsynaptic potential
      • at 6 months, the maximum fEPSP is reduced relative to wild-type MAPT transgenic mice   (MGI Ref ID J:119741)
    • reduced long term potentiation
      • LTP in CA1 region of hippocampus is significantly deteriorated, indicating attenuated postsynaptic responsiveness and compromised synaptic plasticity, but at 6 months no overt reduction in neuron number is detected   (MGI Ref ID J:119741)
  • abnormal amygdala morphology
    • neuron loss is observed at 12 months of age   (MGI Ref ID J:119741)
  • abnormal cerebral cortex morphology
    • at 3 months, mice have neurofilament light chain and tau-positive spheroids in the cerebral cortex   (MGI Ref ID J:119741)
    • prominent atrophy of neocortex is observed at 9 months of age, with a 20% reduction in volume at 12 months of age   (MGI Ref ID J:119741)
  • abnormal entorhinal cortex morphology
    • neuron loss is observed at 12 months of age   (MGI Ref ID J:119741)
  • abnormal hippocampus morphology
    • at 9 months of age, there is marked hippocampal atrophy, with ~25% and ~40% reductions in hippocampal volume at 9 and 12 months of age respectively   (MGI Ref ID J:119741)
    • abnormal dentate gyrus morphology
      • at 3 months, mice have neurofilament light chain and tau-positive spheroids in the dentate gyrus, as well as in the cortex   (MGI Ref ID J:119741)
    • abnormal hippocampal mossy fiber morphology
      • at 3 months but not at 6 months, neurofilament light chain-positive mossy fibers are not detected in CA3 of hippocampus at 3 months but not at 6 months, neurofilament light chain-positive mossy fibers are not detected in CA3 of hippocampus   (MGI Ref ID J:119741)
    • abnormal hippocampus pyramidal cell morphology
      • significant reduction in number in the hippocampal CA3 region is found at 12 months of age, but no loss is detected at 6 months   (MGI Ref ID J:119741)
    • hippocampal neuron degeneration   (MGI Ref ID J:119741)
    • loss of hippocampal neurons
      • up to 6 months, mice show no neuron loss, but by 8 months of age, neuron loss in the hippocampus is seen, becoming more severe in hippocampus, as well as amygdala, neocortex and entorhinal cortex by 12 months of age   (MGI Ref ID J:119741)
  • abnormal spinal cord white matter morphology
    • at 3 months, mice have neurofilament light chain and tau-positive spheroids in the spinal cord white matter   (MGI Ref ID J:119741)
  • astrocytosis
    • microglial activation precedes astrogliosis in brain regions containing NFTs; this is found in the brain and spinal cord, especially in white matter at 3 months of age with increases seen at 6 months in white and gray matter of hippocampus, amygdala, entorhinal cortex and spinal cord   (MGI Ref ID J:119741)
    • gliosis is striking at 6 months in the white matter where little tau pathology exists   (MGI Ref ID J:119741)
    • younger mice (3-4 months) show no overt gliosis but increased microglial activation is detected in the hippocampus   (MGI Ref ID J:119741)
  • brain atrophy
    • limb grasping at 3 months of age is followed by brain atrophy   (MGI Ref ID J:119741)
  • decreased paired-pulse facilitation
    • at 6 months, mice show significantly reduce paired pulse facilitation (PPF) ratio at all stimulus intervals   (MGI Ref ID J:119741)
  • dilated brain ventricles
    • by 8 months of age, ventricular dilatation is seen   (MGI Ref ID J:119741)
  • neurodegeneration
    • mice show progressive neurodegeneration starting at 1 month of age, as determined by increasing loss of synaptophysin immunoreactivity   (MGI Ref ID J:119741)
    • hippocampal neuron degeneration   (MGI Ref ID J:119741)
  • neurofibrillary tangles
    • at 6 months of age, neurofibrillary tangles (NFT) are evident in neocortex, amygdala, hippocampus, brain stem and spinal cord but none are found in mice expressing wild-type human MAPT up to 24 months of age   (MGI Ref ID J:119741)
    • mutants develop ThS-positive neurofibrillary tangles   (MGI Ref ID J:165441)
  • tau protein deposits
    • with aging, brains of mice have increasing levels of insoluble tau deposits composed mainly of transgenic human tau; decrease in solubility of tau is observed between 3 and 6 months   (MGI Ref ID J:119741)
    • at 3 months of age, mutants and mice expressing wild-type transgenic human tau show weak perikaryal and dendritic tau staining mainly in hippocampus, amygdala, cortex, brain stem, and spinal cord; at 6 months, mutants show stronger tau-positive neuronal staining in the hippocampus, amygdala, and spinal cord but older mice expressing wild-type human tau protein show no increases up to 12 months   (MGI Ref ID J:119741)
    • mutants exhibit progression in the distribution of abnormally phosphorylated tau from the entorhinal and neocortex, followed by involvement of the hippocampal formation and subcortical structures, to finally penetration of all layers of the neocortex   (MGI Ref ID J:165441)
  • muscle phenotype
  • dystrophic muscle
    • affected muscles show group atrophies with small angular fibers, indicating chronic denervation of motor neurons   (MGI Ref ID J:119741)
  • progressive muscle weakness
    • mice show motor increasing weakness and neurogenic muscular atrophy after 3 months of age   (MGI Ref ID J:119741)
  • growth/size/body phenotype
  • weight loss
    • slight decrease in weight is seen at 11 months of age   (MGI Ref ID J:165441)

Tg(Prnp-MAPT*P301S)PS19Vle/Tg(Prnp-MAPT*P301S)PS19Vle

        involves: C3H * C57BL/6
  • behavior/neurological phenotype
  • abnormal sexual interaction
    • homozygous females do not mate, so mice have to be maintained as hemizygotes   (MGI Ref ID J:119741)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(Prnp-MAPT*P301S)PS19Vle/0

        B6.Cg-Tg(Prnp-MAPT*P301S)PS19Vle
  • behavior/neurological phenotype
  • abnormal behavior
    • in the Y-maze test, the total percentage of alternations is decreased indicating impaired spontaneous alternation   (MGI Ref ID J:174441)
    • in the Barnes circular maze test, males are able to locate the correct target hole where the escape box had been in the probe trial, however they spend less time around the target hole than wild-type mice   (MGI Ref ID J:174441)
    • abnormal contextual conditioning behavior
      • in the contextual fear conditioning test, mutants show decreased immobility in the fourth time point only   (MGI Ref ID J:174441)
    • abnormal emotion/affect behavior
      • in a portion of the Porsolt forced swim test, mutants show decreased immobility time and increased distance traveled, suggesting that despair-like behavior might be decreased, however, generally over the entire test, no statistical significance is seen for immobility   (MGI Ref ID J:174441)
      • decreased anxiety-related response
        • in the elevated plus-maze test, entries into and time spent on the open arms is increased and in the open field test, time spent in the center of the field is increased, indicating decreased anxiety-like behavior   (MGI Ref ID J:174441)
    • abnormal social investigation
      • in Crawley's three-chamber social approach test, males spend a shorter time with stranger mice than with familiar mice compared to wild-type mice which spend more time with stranger mice, indicating some impaired sociability or object recognition memory   (MGI Ref ID J:174441)
      • however, no differences were seen in the social interaction test of a one-chamber novel environment   (MGI Ref ID J:174441)
    • decreased thermal nociceptive threshold
      • males exhibit decreased thresholds in the hot plate test, indicating increased antinociceptive responses   (MGI Ref ID J:174441)
    • hyperactivity
      • in the open field test, 14 week old males show an increase in total locomotive distance and an increase in stereotypic locomotion   (MGI Ref ID J:174441)
      • in the Y-maze test, males show increased numbers of entries into each arm, total alternations, and total distance traveled indicating hyperactivity   (MGI Ref ID J:174441)
    • increased vertical activity
      • vertical activity of 14 week old males is increased in the latter half of the open field test   (MGI Ref ID J:174441)
  • integument phenotype
  • decreased thermal nociceptive threshold
    • males exhibit decreased thresholds in the hot plate test, indicating increased antinociceptive responses   (MGI Ref ID J:174441)
  • nervous system phenotype
  • increased prepulse inhibition
    • males younger than 6 months of age exhibit lower startle amplitudes than wild-type mice at 110 dB and 120 dB and an increase in percent prepulse inhibition   (MGI Ref ID J:174441)
  • tau protein deposits
    • hyperphosphorylated tau protein accumulation is seen in the lateral globus pallidus, amygdala, auditory cortex, ventral hippocampus, the cingulate cortex, anterior cortical amygdaloid nucleus, and dorsal hippocampus at 4 months of age   (MGI Ref ID J:174441)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Alzheimer's Disease
Neurodegeneration

MAPT related

Neurobiology Research
Alzheimer's Disease
Parkinson's Disease

Tg(Prnp-MAPT*P301S)PS19Vle related

Neurobiology Research
Alzheimer's Disease
      Tau (Mapt) mutants

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(Prnp-MAPT*P301S)PS19Vle
Allele Name transgene insertion PS19, Virginia M Y Lee
Allele Type Transgenic (random, expressed)
Common Name(s) P301S tau (line PS19); PS19 Tg;
Mutation Made By Virginia Lee,   University of Pennsylvania
Strain of Origin(C57BL/6 x C3H)F1
Expressed Gene MAPT, microtubule-associated protein tau, human
Promoter Prnp, prion protein, mouse, laboratory
Molecular Note The transgene construct contains the P301S mutant human microtubule-associated protein tau, MAPT, under the direction of the mouse prion protein, Prnp, promoter. The expression of the mutant human MAPT is 5-fold higher than the expression of the endogenous mouse Mapt protein. [MGI Ref ID J:119741]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(Prnp-MAPT*P301S)PS19Vle alternate2, Standard PCR
Tg(Prnp-MAPT*P301S)PS19Vle QPCR, QPCR
Tg(Prnp-MAPT*P301S)PS19Vle, Standard PCR
Tg(Prnp-MAPT*P301S)PS19Vle-alternate1, Melt Curve Analysis
Tg(Prnp-MAPT*P301S)PS19Vle-alternate1, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Yoshiyama Y; Higuchi M; Zhang B; Huang SM; Iwata N; Saido TC; Maeda J; Suhara T; Trojanowski JQ; Lee VM. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3):337-51. [PubMed: 17270732]  [MGI Ref ID J:119741]

Additional References

Tg(Prnp-MAPT*P301S)PS19Vle related

Carroll JC; Iba M; Bangasser DA; Valentino RJ; James MJ; Brunden KR; Lee VM; Trojanowski JQ. 2011. Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy. J Neurosci 31(40):14436-49. [PubMed: 21976528]  [MGI Ref ID J:177434]

Chakravarthy B; Gaudet C; Menard M; Brown L; Atkinson T; Laferla FM; Ito S; Armato U; Dal Pra I; Whitfield J. 2012. Reduction of the immunostainable length of the hippocampal dentate granule cells' primary cilia in 3xAD-transgenic mice producing human Abeta(1-42) and tau. Biochem Biophys Res Commun 427(1):218-22. [PubMed: 22995307]  [MGI Ref ID J:190096]

Dumont M; Stack C; Elipenahli C; Jainuddin S; Gerges M; Starkova N; Calingasan NY; Yang L; Tampellini D; Starkov AA; Chan RB; Di Paolo G; Pujol A; Beal MF. 2012. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet 21(23):5091-105. [PubMed: 22922230]  [MGI Ref ID J:188924]

Dumont M; Stack C; Elipenahli C; Jainuddin S; Gerges M; Starkova NN; Yang L; Starkov AA; Beal F. 2011. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J 25(11):4063-72. [PubMed: 21825035]  [MGI Ref ID J:178410]

Hurtado DE; Molina-Porcel L; Carroll JC; Macdonald C; Aboagye AK; Trojanowski JQ; Lee VM. 2012. Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease. J Neurosci 32(21):7392-402. [PubMed: 22623685]  [MGI Ref ID J:184975]

Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM. 2010. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177(4):1977-88. [PubMed: 20802182]  [MGI Ref ID J:165441]

Ji B; Maeda J; Sawada M; Ono M; Okauchi T; Inaji M; Zhang MR; Suzuki K; Ando K; Staufenbiel M; Trojanowski JQ; Lee VM; Higuchi M; Suhara T. 2008. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 28(47):12255-67. [PubMed: 19020019]  [MGI Ref ID J:142367]

Maeda J; Zhang MR; Okauchi T; Ji B; Ono M; Hattori S; Kumata K; Iwata N; Saido TC; Trojanowski JQ; Lee VM; Staufenbiel M; Tomiyama T; Mori H; Fukumura T; Suhara T; Higuchi M. 2011. In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-{beta} and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders. J Neurosci 31(12):4720-4730. [PubMed: 21430171]  [MGI Ref ID J:170310]

Mewes A; Franke H; Singer D. 2012. Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies. PLoS One 7(9):e45017. [PubMed: 22984603]  [MGI Ref ID J:192890]

Min SW; Cho SH; Zhou Y; Schroeder S; Haroutunian V; Seeley WW; Huang EJ; Shen Y; Masliah E; Mukherjee C; Meyers D; Cole PA; Ott M; Gan L. 2010. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953-66. [PubMed: 20869593]  [MGI Ref ID J:167861]

Takeuchi H; Iba M; Inoue H; Higuchi M; Takao K; Tsukita K; Karatsu Y; Iwamoto Y; Miyakawa T; Suhara T; Trojanowski JQ; Lee VM; Takahashi R. 2011. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One 6(6):e21050. [PubMed: 21698260]  [MGI Ref ID J:174441]

Yamada K; Cirrito JR; Stewart FR; Jiang H; Finn MB; Holmes BB; Binder LI; Mandelkow EM; Diamond MI; Lee VM; Holtzman DM. 2011. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31(37):13110-7. [PubMed: 21917794]  [MGI Ref ID J:191549]

Yata K; Oikawa S; Sasaki R; Shindo A; Yang R; Murata M; Kanamaru K; Tomimoto H. 2011. Astrocytic neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse. Brain Res 1410:12-23. [PubMed: 21803337]  [MGI Ref ID J:175758]

Yoshiyama Y; Kojima A; Itoh K; Uchiyama T; Arai K. 2012. Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model. Neurobiol Dis 45(1):329-36. [PubMed: 21889983]  [MGI Ref ID J:179843]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX10

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice can be bred as hemizygotes. These mice cannot be bred to homozygosity as homozygous females do not mate.
Mating SystemNoncarrier x Hemizygote         (Female x Male)   11-JUL-08
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHemizygous for Tg(Prnp-MAPT*P301S)PS19Vle  
Price per Pair (US dollars $)Pair Genotype
$302.00Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle x Noncarrier  
$302.00Noncarrier x Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1500 unique mouse models across a vast array of research areas. Breeding colonies provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. If a Repository strain is not immediately available, then within 2 to 3 business days, you will receive an estimated availability timeframe for your inquiry or order along with various delivery options. Repository strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping. We will note and try to accommodate requests for specific ages of Repository strains but cannot guarantee provision of these strains at specific ages. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, please let us know.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHemizygous for Tg(Prnp-MAPT*P301S)PS19Vle  
Price per Pair (US dollars $)Pair Genotype
$392.60Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle x Noncarrier  
$392.60Noncarrier x Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1500 unique mouse models across a vast array of research areas. Breeding colonies provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. If a Repository strain is not immediately available, then within 2 to 3 business days, you will receive an estimated availability timeframe for your inquiry or order along with various delivery options. Repository strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping. We will note and try to accommodate requests for specific ages of Repository strains but cannot guarantee provision of these strains at specific ages. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, please let us know.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1500 unique mouse models across a vast array of research areas. Breeding colonies provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. If a Repository strain is not immediately available, then within 2 to 3 business days, you will receive an estimated availability timeframe for your inquiry or order along with various delivery options. Repository strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping. We will note and try to accommodate requests for specific ages of Repository strains but cannot guarantee provision of these strains at specific ages. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, please let us know.

Control Information

  Control
   Noncarrier
   100010 B6C3F1/J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)